ISONIAZIDE

Isoniazide (isoniazid) inhibits mycolic acid synthesis in Mycobacterium tuberculosis. Side effects include hepatotoxicity, neuropathy (preventable with B6), rash, and CNS effects. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

ISONIAZIDE demonstrates a highgranularity biochemical interaction profile spanning catalyticdomain modulation, multilayer signalling interference, mitochondrialnetwork recalibration, redoxstate restructuring, ionflux redistribution, membraneelectrochemical modulation, cytoskeletalarchitecture remodelling and transcriptionfactor axis reprogramming. Its molecular topology supports interactions with catalytic residues, allosteric regulatory surfaces, transmembrane helices, hydrophobic receptor pockets, nucleotidebinding cavities, redox-buffer modules and polymeric scaffolding proteinsenabling broad influence across metabolic, genomic, electrophysiological and structural regulatory networks.

Mechanistically, ISONIAZIDE may reshape phosphorylationflow geometry across ERK/MAPK/JNK/p38 cascades, modulate PI3KAKT survivalpathway architecture, alter Gprotein coupling logic, redistribute Ca²⁺ microdomains, shift IP/DAG signal amplitude, and recalibrate cAMPPKA oscillatory behaviour. Mitochondrial effects include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, mitochondrialmembrane potential polarity shifts and ERmitochondria bidirectional stresssignal integration.

Advanced

  • Kinomescale catalyticcascade interference and pathway reconstruction
  • Ultraresolution receptor/ligand docking and conformationaltransition modelling
  • UPR/ERstress, mitophagy, autophagy and oxidativestress crosstalk research
  • Deep multiomics network reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal tensionmapping, polymer turnover and mechanosignalling analytics
  • Apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos modelling
  • Machinelearning SAR/QSAR pipelines for predictive molecular optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation and antioxidantbuffer system collapse
  • Mitochondrial fragmentation, membranepotential failure or ETC inhibition
  • Severe Na⁺/K⁺/Ca²⁺ ionhomeostasis disruption
  • Cytoskeletal depolymerisation, actin/tubulin instability and loss of cellular mechanics
  • membrane-integrity failure and lipidbilayer thinning
  • NF-κB, STAT and IRF inflammatoryaxis hyperactivation
  • Engagement of multiaxis programmed-cell-death pathways
  • Epigenetic drift across methylation/acetylation domains

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C6H7N3O

Molecular Weight

137.14 g/mol

CAS Number

54-85-3

Storage Condition

Store below 40 °C (104 °C), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight, light-resistant container. Protect from freezing. NOTE: Crystallization may occur at low temperatures. Upon warming to room temperature, the crystals will redissolve.

Solubility

greater than or equal to 100 mg/mL at 77 °F (NTP, 1992)

Purity

Purity information is available upon request (COA).

Synonym

isoniazid; 54-85-3; Isonicotinic acid hydrazide; Isonicotinohydrazide; pyridine-4-carbohydrazide

IUPAC/Chemical Name

pyridine-4-carbohydrazide

InChl Key

QRXWMOHMRWLFEY-UHFFFAOYSA-N

InChl Code

InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

References

https://pubchem.ncbi.nlm.nih.gov/compound/3767;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download